L
1.27
-0.02 (-1.17%)
| Previous Close | 1.28 |
| Open | 1.25 |
| Volume | 71,262 |
| Avg. Volume (3M) | 179,226 |
| Market Cap | 12,400,883 |
| Price / Sales | 34.66 |
| 52 Weeks Range | |
| Earnings Date | 14 May 2025 |
| Operating Margin (TTM) | -7,114.92% |
| Diluted EPS (TTM) | -6.68 |
| Current Ratio (MRQ) | 0.550 |
| Operating Cash Flow (TTM) | -16.01 M |
| Levered Free Cash Flow (TTM) | -12.16 M |
| Return on Assets (TTM) | -272.95% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | SeaStar Medical Holding Corpora | Mixed | Mixed |
AIStockmoo Score
1.0
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.0 |
| Average | 1.00 |
|
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 2.08% |
| % Held by Institutions | 2.18% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 07 May 2025 | Announcement | SeaStar Medical to Report First Quarter Financial Results on May 14, 2025 |
| 30 Apr 2025 | Announcement | SeaStar Medical Announces CEO Interview on Benzinga All Access to Occur Today at Approximately 10:50 am Eastern Time |
| 08 Apr 2025 | Announcement | FDA Grants SeaStar Medical Two New Breakthrough Device Designations for SCD Therapy to Treat Systemic Inflammatory Response in Adult and Pediatric Patients Undergoing Cardiac Surgery |
| 27 Mar 2025 | Announcement | SeaStar Medical Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates |
| 24 Mar 2025 | Announcement | SeaStar Medical to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025 |
| 18 Mar 2025 | Announcement | NKF Honors SeaStar Medical, with 2025 Corporate Innovator Award |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |